Otuska Extends Collaboration With Gelanea On Schizophrenia Drug Research
This article was originally published in PharmAsia News
Otsuka Pharmaceutical and American firm Galenea agreed to extend joint research and development of novel therapies for schizophrenia and other central nervous system diseases. The two companies started the collaboration in January 2005 and the new agreement extended the period from five years to six years. According to the agreement, Otsuka will pay as much as $75 million in research fees to Galenea. Galenea targets the relationship between calcineurin and CNS and is developing drug candidates to treat schizophrenia. (Click here for more - Japanese language
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"